> Details

Bamias, Giorgos; Kokkotis, Georgios; Christidou, Angeliki; Christodoulou, Dimitrios K.; Delis, Vasileios; Diamantopoulou, Georgia; Fessatou, Smaragdi; Gatopoulou, Anthia; Giouleme, Olga; Kafritsa, Panagiota; Kalantzis, Chrisostomos; Kapsoritakis, Andreas; Karatzas, Pantelis; Karmiris, Konstantinos; Katsanos, Konstantinos; Kevrekidou, Polyxeni; Kosmidis, Charalampos; Mantaka, Aikaterini; Mathou, Nicoletta; Michalopoulos, George; Michopoulos, Spyridon; Papaconstantinou, Ioannis; Papatheodoridis, George; Polymeros, Dimitrios; [...]

The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD
  • Contributor: Bamias, Giorgos; Kokkotis, Georgios; Christidou, Angeliki; Christodoulou, Dimitrios K.; Delis, Vasileios; Diamantopoulou, Georgia; Fessatou, Smaragdi; Gatopoulou, Anthia; Giouleme, Olga; Kafritsa, Panagiota; Kalantzis, Chrisostomos; Kapsoritakis, Andreas; Karatzas, Pantelis; Karmiris, Konstantinos; Katsanos, Konstantinos; Kevrekidou, Polyxeni; Kosmidis, Charalampos; Mantaka, Aikaterini; Mathou, Nicoletta; Michalopoulos, George; Michopoulos, Spyridon; Papaconstantinou, Ioannis; Papatheodoridis, George; Polymeros, Dimitrios; [...]
  • Published: Ovid Technologies (Wolters Kluwer Health), 2021
  • Published in: European Journal of Gastroenterology & Hepatology, 33 (2021) 1S, Seite e810-e817
  • Language: English
  • DOI: 10.1097/meg.0000000000002267
  • ISSN: 0954-691X
  • Keywords: Gastroenterology ; Hepatology
  • Origination:
  • Footnote:
  • Description: <jats:sec> <jats:title>Objectives</jats:title> <jats:p>COVID-19 has evolved into a global health crisis, variably affecting the management of patients with chronic illnesses. Patients with inflammatory bowel disease (IBD) may represent a vulnerable population due to frequent administration of immune-modifying treatments. We aimed to depict the natural history of COVID-19 infection in Greek patients with IBD at a nationwide level via unbiased reporting of all cases that were registered during the sequential waves of the pandemic.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Following a national call from the Hellenic Society for the study of IBD, we enrolled all IBD patients with established diagnoses of COVID-19. Clinical and epidemiological data, including COVID-19 modifying factors and IBD-associated therapies, were analyzed against adverse outcomes (hospitalization, ICU admission and death).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We identified 154 IBD patients who were diagnosed with COVID-19 (men: 58.4%; mean age=41.7 years [SD = 14.9]; CD: 64.3%). Adverse outcomes were reported in 34 patients (22.1%), including 3 ICU admissions (1.9%) and two deaths (1.3%). Multivariate logistic regression analysis showed that age (OR = 1.04, 95% CI, 1–1.08) and dyspnea at presentation (OR = 7.36, 95% CI, 1.84–29.46) were associated with worse outcomes of COVID-19 infection. In contrast, treatment with biologics, in particular anti-TNF agents, exerted a protective effect against an unfavorable COVID-19 disease course (OR = 0.4, 95% CI, 0.16–0.99). Patients on subcutaneous biologics were more likely to halt treatment due to the infection as compared to those on intravenous biologics.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>IBD patients who developed COVID-19 had a benign course with adverse outcomes being infrequent. Treatment with anti-TNF biologics had a protective effect, thus, supporting continuation of therapy during the pandemic.</jats:p> </jats:sec>